Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Thoracic 3Head & Neck 3Gynecologic 3Gastrointestinal 3Tumor-Agnostic 2Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 610Radiotherapy 387Bevacizumab 253Magnetic Resonance Spectroscopy 202Cyclophosphamide 177Carboplatin 159Radiosurgery 145Etoposide 132Radiation 120Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 81Lomustine 80Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Population Groups × CNS × Clear all
NCT00072358 2022-05-16

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
291 enrolled 7 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡